Zacks Research Issues Pessimistic Forecast for CORT Earnings

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Analysts at Zacks Research dropped their Q3 2026 earnings estimates for shares of Corcept Therapeutics in a report issued on Tuesday, March 17th. Zacks Research analyst Team now expects that the biotechnology company will post earnings per share of $0.21 for the quarter, down from their previous forecast of $0.30. Zacks Research has a “Strong Sell” rating on the stock. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.36 per share. Zacks Research also issued estimates for Corcept Therapeutics’ FY2028 earnings at $3.02 EPS.

A number of other analysts also recently commented on the company. UBS Group started coverage on Corcept Therapeutics in a research report on Tuesday, December 16th. They issued a “neutral” rating and a $95.00 price objective for the company. Wolfe Research cut Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 price objective on the stock. in a research report on Wednesday, December 31st. HC Wainwright cut their target price on Corcept Therapeutics from $105.00 to $67.00 and set a “buy” rating for the company in a research note on Friday, February 20th. Truist Financial set a $50.00 target price on Corcept Therapeutics in a research report on Wednesday, December 31st. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Corcept Therapeutics in a research note on Monday, December 29th. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $77.17.

Corcept Therapeutics Trading Up 2.3%

Shares of CORT opened at $34.08 on Thursday. Corcept Therapeutics has a 12-month low of $28.66 and a 12-month high of $117.33. The company has a quick ratio of 2.85, a current ratio of 2.92 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $3.63 billion, a price-to-earnings ratio of 41.56 and a beta of 0.29. The stock’s 50-day moving average price is $37.52 and its 200 day moving average price is $62.18.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $0.20 EPS for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.13). Corcept Therapeutics had a net margin of 12.96% and a return on equity of 15.19%. The company had revenue of $202.13 million for the quarter, compared to analyst estimates of $254.94 million. During the same period in the prior year, the company posted $0.26 EPS. The firm’s quarterly revenue was up 11.1% on a year-over-year basis.

Hedge Funds Weigh In On Corcept Therapeutics

Several institutional investors have recently added to or reduced their stakes in CORT. Pathstone Holdings LLC increased its stake in shares of Corcept Therapeutics by 0.8% during the third quarter. Pathstone Holdings LLC now owns 18,013 shares of the biotechnology company’s stock worth $1,497,000 after purchasing an additional 144 shares during the period. Campbell Newman Asset Management Inc. boosted its stake in Corcept Therapeutics by 0.5% in the 3rd quarter. Campbell Newman Asset Management Inc. now owns 35,530 shares of the biotechnology company’s stock valued at $2,953,000 after purchasing an additional 170 shares during the period. Clearstead Advisors LLC grew its holdings in Corcept Therapeutics by 163.6% in the 3rd quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company’s stock valued at $26,000 after buying an additional 193 shares in the last quarter. Gould Capital LLC grew its holdings in Corcept Therapeutics by 50.0% in the 3rd quarter. Gould Capital LLC now owns 600 shares of the biotechnology company’s stock valued at $50,000 after buying an additional 200 shares in the last quarter. Finally, Advisors Asset Management Inc. increased its position in Corcept Therapeutics by 1.3% during the 2nd quarter. Advisors Asset Management Inc. now owns 18,935 shares of the biotechnology company’s stock worth $1,390,000 after buying an additional 237 shares during the period. 93.61% of the stock is owned by institutional investors.

Insider Activity at Corcept Therapeutics

In other Corcept Therapeutics news, insider William Guyer sold 8,233 shares of the company’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $35.99, for a total value of $296,305.67. Following the sale, the insider directly owned 2,231 shares in the company, valued at $80,293.69. This represents a 78.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director G Leonard Baker, Jr. acquired 100,000 shares of the business’s stock in a transaction on Tuesday, March 17th. The shares were bought at an average cost of $33.14 per share, with a total value of $3,314,000.00. Following the completion of the acquisition, the director owned 1,146,631 shares of the company’s stock, valued at approximately $37,999,351.34. This trade represents a 9.55% increase in their position. The SEC filing for this purchase provides additional information. Over the last quarter, insiders sold 48,233 shares of company stock worth $1,817,306. Corporate insiders own 20.80% of the company’s stock.

Key Corcept Therapeutics News

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Director G. Leonard Baker Jr. purchased 100,000 CORT shares at an average $33.14 on March 17, increasing his stake by ~9.6% — a high‑confidence insider buy that can be interpreted as constructive for the company’s near‑term sentiment. SEC Form 4
• Neutral Sentiment: Reported short‑interest data for March is inconsistent/zero (shows 0 shares and NaN change), so there’s no clear short‑seller pressure signal to explain intraday moves; treat this data as unreliable until clarified by an exchange or reporting agent.
• Negative Sentiment: Multiple shareholder‑rights firms have issued class‑action notices and deadline alerts (lead‑plaintiff deadline April 21, 2026) related to alleged disclosure problems covering Oct 31, 2024–Dec 30, 2025; Hagens Berman’s notice specifically cites an FDA rejection and a federal court patent loss as catalysts for the litigation — these legal and regulatory issues raise potential financial and reputational risk. Hagens Berman Notice
• Negative Sentiment: Zacks Research cut Q3 2026 EPS estimates to $0.21 (from $0.30) and issued a “Strong Sell” rating; the downgrade signals weaker near‑term earnings expectations from at least one sell‑side source, which can pressure valuation and sentiment. (Research note disclosed March 17.)

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.